logo-loader
viewBed Bath & Beyond Inc.

Bed Bath & Beyond slip further after second quarter results disappoint

The retailer said that it "is undertaking a number of transformational initiatives," which it will discuss in a conference call later Wednesday

1505909977_shutterstock_129405830.jpg
The retailer said second-quarter profit came in at US$94.2mln , or 67 US cents a share, on sales of US$2.9bn.

Bed Bath & Beyond Inc. (NASDAQ;BBBY) saw its shares plunge further premarket Wednesday after the company released below market second quarter results yesterday.

Blaming restructuring and Hurricane Harvey, the retailer said second-quarter profit came in at US$94.2mln, or 67 US cents a share, on sales of US$2.9bn, against a year ago’s US$1.11 a share on revenue of US$2.99bn.

This was well below Wall Street’s expectations for 93 US cents a share on sales of US$3bn.

Transformational initiatives underway

Bed Bath & Beyond said restructuring charges (8 US cents a share), Hurricane Harvey impacts (2 US cents a share) and a new accounting standard (a penny a share) impacted the results.

The retailer said in a statement that it "is undertaking a number of transformational initiatives," which it will discuss in a conference call later Wednesday.

Trading was halted for the stock ahead of the announcement. Its share price dipped more than 18% in after-hours after trading resumed; shares closed down 1% at US$27.03 on Tuesday.

In premarket Wednesday, its shares plunged further, down 15.46% at US$22.85.

Quick facts: Bed Bath & Beyond Inc.

Price: 11.81 USD

NASDAQ:BBBY
Market: NASDAQ
Market Cap: $1.48 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

1 hour, 26 minutes ago

2 min read